

OBSERVATIONS

Comparison of Glycemic and Lipid Response to Pioglitazone Treatment in Mexican-Americans and Non-Hispanic Caucasians With Type 2 Diabetes

The risk of type 2 diabetes in Mexican-Americans is almost twice that of non-Hispanic Caucasians (1). Mexican-Americans are also, in general, more likely to have insulin resistance, impaired fasting glucose, and impaired glucose tolerance than non-Hispanic Caucasians (1,2). Given these increased risks of type 2 diabetes in the Mexican-American population and the fact that poor glycemic control is more common in diabetic Mexican-Americans than in non-Hispanic Caucasians (3), it is important to consider the efficacy of diabetes therapy in this specific population.

In a retrospective chart review, our clinic identified patients with type 2 diabetes who had been treated with pioglitazone 45 mg/day for 6 or more months without interruption. Patient charts were then selected if HbA_{1c} and lipids were available within 4 weeks of starting treatment and ~4 months into treatment. Patients whose lipid-lowering medication was changed during this same time period were excluded. In total, data from 98 non-Hispanic Caucasians and 81 Mexican-Americans were reviewed.

The majority of patients (>75%) were taking pioglitazone in combination with metformin, sulfonylurea, or insulin, with the remainder of the patients receiving pioglitazone as monotherapy. The percentage of patients on monotherapy was the same in both groups. Fifty-three percent of non-Hispanic and 31% of Mexican-American patients were taking statin medication ($P = 0.002$). One patient in the Mexican-American group and three in the non-Hispanic group were taking a fibrate. Baseline characteristics (duration of

diabetes, BMI, C-peptide, and male-to-female ratio) for the two groups were similar with the exception of age. The mean and standard deviation for age was 61.2 ± 12.8 years in the non-Hispanic Caucasian population and 52.7 ± 15.2 in the Mexican-American population ($P < 0.001$). The younger age in the Mexican-American population is consistent with the younger age of onset of diabetes that has been reported elsewhere for this population (4). The mean duration of treatment, at which time the laboratory data were obtained, was 3.9 months in the Mexican-American patients and 4.4 months in the non-Hispanic Caucasians ($P = 0.312$).

Our analysis showed that mean reduction in HbA_{1c} was similar between the two populations. Mean baseline HbA_{1c} was $8.0 \pm 1.9\%$ for non-Hispanics and $8.2 \pm 1.9\%$ for Mexican-Americans. At 3 months, the mean reductions from baseline were $1.2 \pm 1.8\%$ and $1.1 \pm 1.4\%$, respectively (the difference between two populations was not statistically significant, $P = 0.616$).

Similarly, there was no difference between the two populations in terms of lipid effects. Baseline triglyceride levels were 216 and 207 mg/dl, respectively; baseline HDL cholesterol levels were 41.6 and 43.1 mg/dl, respectively; and baseline LDL cholesterol levels were 106 and 113 mg/dl, respectively. Mean reductions in triglycerides from baseline were $10.1 \pm 47.1\%$ in non-Hispanic Caucasians and $8.4 \pm 47.3\%$ in Mexican-Americans ($P = 0.802$ for two populations). Mean increases in HDL cholesterol were 17.0 ± 21.0 and $16.0 \pm 18.8\%$, respectively ($P = 0.748$), and mean increases in LDL cholesterol were 5.1 ± 25.2 and $6.5 \pm 48.1\%$, respectively ($P = 0.826$). In a subanalysis, there was no significant ($P > 0.05$) difference within each ethnic group in the lipid response to pioglitazone regardless of whether the patient was concurrently taking a statin.

Also of interest was the fact that weight gain was similar in both groups. Baseline BMI was practically identical between the two population groups (33.9 and 33.1 kg/m², respectively, for non-Hispanics Caucasians vs. Mexican-Americans), although overall, the Caucasians weighed more at baseline than the Mexican-Americans (mean weight 99.6 and 89.2 kg, respectively).

Mean weight gain at 3 months was 1.64 and 1.41 kg, respectively ($P = 0.540$).

Although Mexican-Americans have a higher incidence of type 2 diabetes and an earlier age of onset, our analysis suggests that their response to treatment with pioglitazone is similar to that seen in non-Hispanic Caucasians in terms of HbA_{1c} and lipid changes. Such a comparison of pioglitazone treatment between these two ethnic groups has not previously been conducted, and thus these data provide some interesting and encouraging insights. Certainly, good glycemic control can greatly reduce the risk for diabetic complications in all ethnic groups; however, because of the increased risk in Mexican-Americans, treatments that improve glycemic control potentially offer a greater benefit in this population (5). Further prospective comparative studies in Mexican-American populations should be conducted to confirm and expand upon our results.

ALLEN B. KING, MD, FACP, FACE, CDE
DANA U. ARMSTRONG, RD, CDE
SITHIPHOL CHINNAPONGSE, MD

From the Diabetes Care Center, Salinas, California.

Address correspondence to Allen B. King, Diabetes Care Center, 1260 Main St. S., Suite 201, Salinas, CA 93901. E-mail: aking@diabetescarecenter.com.

A.B.K. is a member of the National Actos Product Advisory Committee and has received honoraria from Takeda Pharmaceuticals.

References

- Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer H-M, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey 1988–1994. *Diabetes Care* 21:518–524, 1998
- Chiu KC, Chuang L-M, Yoon C: Comparison of measured and estimated indices of insulin sensitivity and beta cell function: impact of ethnicity on insulin sensitivity and beta cell function in glucose-tolerant and normotensive subjects. *J Clin Endocrinol Metab* 86:1620–1625, 2001
- Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care* 22:403–408, 1999
- Stern MP, Haffner SM: Type II diabetes and its complications in Mexican Americans. *Diabet Metab Rev* 6:29–45, 1990
- de Lissovoy G, Ganaczy DA, Ray NF: Relationship of hemoglobin A1c, age of dia-

betes diagnosis and ethnicity to clinical outcomes and medical costs in a computer-simulated cohort of persons with type 2 diabetes. *Am J Manag Care* 6:573–584, 2000

Diabetic Vasculopathy and Alcohol Tolerance Trait in Type 2 Diabetes

In 1978, Pyke and Leslie (1,2) first proposed the hypothesis that clinical pictures of patients with type 2 diabetes can be characterized by two clinical presentations in response to chlorpropamide use and tolerance to alcohol. Chlorpropamide alcohol flushing (CPAF) is often observed in diabetic patients with a family history of diabetes, but among those patients without CPAF, there is a high probability of developing severe diabetic retinopathy. Subsequently, Barnett et al. (3) has reported that persistent proteinuria is also more commonly observed in patients without CPAF. However, the role and significance of CPAF and diabetic vasculopathy still remains controversial.

Aldehyde dehydrogenase-2 (ALDH2) and alcohol dehydrogenase-2 (ADH2) are the key enzymes for alcohol metabolism. Many Asians lack enzyme activity of ALDH2 and have superactive enzyme activity of ADH2, attributed to point mutations within both structural genes (4). Hence, the expression of these two enzyme mutations could determine the alcohol tolerance among the Japanese population.

We have found an increase in the prevalence of nephropathy and advanced diabetic retinopathy among Japanese patients with diabetes and a specific ADH2 and ALDH2 genotype. A total of 158 patients with type 2 diabetes (114 men and 44 women aged 17–81 years) were examined. The subjects were consecutively selected from our outpatient clinic and were all unrelated. After informed consent, a blood sample was obtained from each subject. Genotyping of ALDH2 and ADH2 was performed by the PCR-restriction fragment–length polymorphism (RFLP) method, details described elsewhere (4). The phenotype of ALDH2 inactivity is compatible with possession of

the genotype ALDH2*1/ALDH2*2 or ALDH2*2/ALDH2*2, and the phenotype of ADH2 superactivity is compatible with possession of the genotype ADH2*2/ADH2*2 (4). Diabetic retinopathy was assessed and categorized by ophthalmologist examination. Nephropathy was diagnosed if proteinuria was found on testing with CLINITEK-200+ (Bayer Medical) on at least three consecutive clinic visits in the absence of other causes of proteinuria.

The results of this study showed that 41 subjects have active ALDH2 and superactive ADH2 genotypes, which was regarded as the alcohol tolerance (ATO) group. The other 117 subjects were regarded as the alcohol intolerance (AIT) group, because these patients had usual ADH2 and/or inactive ALDH2 genotypes, which accounts for delayed alcohol metabolism. There was no difference between the two groups in sex, age, age of diabetes onset, duration of diabetes, height, BMI, fasting plasma glucose, and HbA_{1c} level (for ATO vs. AIT, respectively, male/female 28/13 vs. 86/31, age 59.1 ± 9.6 vs. 57.7 ± 11.2 years, onset of diabetes 47.6 ± 10.4 vs. 46.5 ± 12.4 years, duration 11.7 ± 7.3 vs. 11.0 ± 7.7 years, height 161.3 ± 9.7 vs. 162.9 ± 7.9 cm, BMI 23.2 ± 3.9 vs. 22.8 ± 3.4 kg/m², fasting plasma glucose 149.5 ± 38.9 vs. 146.5 ± 42.4 mg/dl, and HbA_{1c} 7.8 ± 1.4 vs. 7.8 ± 1.3%). However, the ATO group had a higher frequency of having persistent proteinuria than the AIT group (ATO 15 of 41, 36.6%; AIT 24 of 117, 20.5%; $P < 0.05$ by χ^2 analysis). Among all, retinopathy was found in 31.7% (13 of 41) of the ATO group and in 32.5% (38/117) of the AIT group, showing no difference. However, among the patients with retinopathy, the frequency of proliferative retinopathy was three times higher in the ATO group (5 of 13, 38.5%) than in the AIT group (5 of 38, 13.2%) ($P < 0.05$). Thus, the ATO group had higher frequency of having nephropathy and of developing diabetic proliferative retinopathy than the AIT group.

It has been noted that activation of protein kinase C (PKC)- β under hyperglycemia can lead to a number of downstream sequelae, which are potentially damaging to the vascularity of glomerulus and retina in diabetes (5). ADH and ALDH are the enzymes not only for alcohol metabolism, but also for degradation of 4-hydroxy-2-nonenal (4-HNE) and

other aldehydes (6–8). 4-HNE is a by-product of lipid peroxidation and has a role in pathophysiological conditions by acting as a signal molecule able to modulate relevant biological events, such as cell signaling, gene expression, cell proliferation, and cell differentiation. Interestingly, Chiarpotto et al. (9) has reported on differential regulation of protein PKC isoforms by a concentration of 4-HNE that is actually detectable in specific biological fluids or tissues. PKC- β I and PKC- β II activities are markedly increased by 0.1 μ mol/l 4-HNE, whereas they are unaffected or even inhibited by 1–10 μ mol/l 4-HNE. Decreased tissue levels of 4-HNE could result from active ALDH2 and superactive ADH2 expression, as represented by subjects of the ATO group (6–8). Therefore, we speculate, in the ATO group, that the 4-HNE in the low micromolar range is able to have an influence on cell function through upregulation of PKC- β isoforms, which aggravates the damaging effects of PKC- β isoforms induced by hyperglycemia. Then, in the chronic situation, the lower concentration trait of 4-HNE in the ATO group may account for the long-term development of diabetic nephropathy and severe retinopathy.

In conclusion, we suggest that in Japanese individuals, the alcohol tolerance genetic trait is associated with the occurrence of diabetic vasculopathy. Our finding seemingly has a similar importance to that of the CPAF hypothesis, in terms of a suggestion for a relationship between alcohol tolerance and diabetic vasculopathy (2,3).

Acknowledgments—The authors thank Dr. R. Arakaki for help in preparation of the manuscript.

YOSHIHIKO SUZUKI, MD^{1,2,3}
MATSUO TANIYAMA, MD²
TAROU MURAMATSU, MD⁴
SUSUMU HIGUCHI, MD⁵
SHIGEO OHTA, PhD³
YOSHIHIITO ATSUMI, MD¹
KEMPEI MATSUOKA, MD¹

From ¹Saiseikai Central Hospital, Tokyo, Japan; ²Fujigaoka Hospital, Showa University, Kanagawa, Japan; the ³Department of Biochemistry and Cell Biology, Institute of Gerontology, Nippon Medical School, Kanagawa, Japan; the ⁴Department of Neuropsychiatry, Keio University, Tokyo, Japan; and the ⁵National Institute of Alcoholism, Kurihama National Hospital, Kanagawa, Japan.

Address correspondence to Y. Suzuki, MD, Sai-

seikai Central Hospital, 1-4-17, Mita, Minato-ku, Tokyo, 108 Japan. E-mail: drszuzuki@ba2.so-net.ne.jp.



References

1. Pyke DA, Leslie RDG: Chlorpropamide-alcohol flushing: a definition of its relation to non-insulin-dependent diabetes. *BMJ* 2:1521-1522, 1978
2. Leslie RDG, Pyke DA: Chlorpropamide alcohol flushing and diabetic retinopathy. *Lancet* 12:997-999, 1979
3. Barnett AH, Leslie RDG, Pyke DA: Chlorpropamide-alcohol flushing and proteinuria in non-insulin-dependent diabetics. *BMJ* 282:522-523, 1981
4. Muramatsu T, Wang Zu-Cheng, Fang Yi-Ru, Hu B, Yan H, Yamada K, Higuchi S, Harada S, Kono H: Alcohol and aldehyde dehydrogenase genotypes and drinking behavior of Chinese living in Shanghai. *Hum Gene* 96:151-154, 1995
5. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. *Diabetes* 47:859-866, 1998
6. Hartly DP, Petersen DR: Co-metabolism of ethanol, ethanol-derived acetaldehyde, and 4-hydroxynonenal in isolated rat hepatocytes. *Alcohol Clin Exp Res* 21:298-304, 1997
7. Vasiliou V, Pappa A: Polymorphisms of human aldehyde dehydrogenases. *Pharmacology* 61:192-198, 2000
8. Esberbauer H, Zolliner H, Lang J: Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. *Biochem J* 228:363-373, 1985
9. Chiarpotto E, Domenicotti C, Paola D, Vitali A, Nitti M, Pronzato MA, Biasi F, Cottalasso D, Marinari UM, Dragonetti A, Cesaro P, Isidoro C, Poli G: Regulation of rat hepatocyte protein kinase C beta isoenzymes by the lipid peroxidation product 4-hydroxy-2,3-nonenal: a signaling pathway to modulate vesicular transport of glycoproteins. *Hepatology* 29:1565-1572, 1999

Screening Using Compressed Digital Retinal Images Successfully Identifies Retinopathy

Digital retinal photographs can be integrated into a computerized network that more easily enables communication and quality assurance (1). Image compression overcomes the

difficulty of transmitting and storing large file sizes. Concern has been raised that major compression of $\geq 70\%$ results in clinically significant loss of retinal detail with inadequate screening sensitivities (2). It is unclear whether low levels of compression result in loss of screening sensitivity compared with the original bit-map image.

We used a Topcon TRC-NW6S nonmydriatic fundus camera with a Sony DXC950P to photograph 171 patients with diabetes (one eye each for the study), without the use of mydriasis. Original bit-map images (768 \times 576 pixels, 1.27 MB) were stored and compressed to make a JPEG image (104 KB) of the highest quality using Paintshop Pro (Jasc Software, Eden Prairie, MN) with standard encoding. All images were anonymized and presented to the grader in random order. Images were graded on a 17-inch Cathode ray tube monitor with 1,024 \times 768 pixel resolution in a darkened room by a single grader. Severe and very severe nonproliferative retinopathy, proliferative retinopathy, and maculopathy were defined as vision-threatening retinopathy.

On the original bit-map images, 80 patients had normal retina (46.7%), 35 had background retinopathy (20.5%), 38 had vision-threatening retinopathy (22.2%), 5 proliferative and 33 maculopathy, 8 had non-diabetes-related changes (4.7%), and 10 were unreadable (5.8%). Compared with bit-map images, grading using the JPEG images achieved a sensitivity of 95.8% ($\pm 5.1\%$, 95% CI) and a specificity of 95.0% ($\pm 4.2\%$) in the detection of any identifiable disease. This yields a positive predictive value of 94.6% and a negative predictive value of 96.2%. In terms of identifying vision-threatening retinopathy, the sensitivity of using highest-quality compressed JPEG images was 97.4% ($\pm 2.4\%$) with a specificity of 100%. The positive predictive value was 100%, and the negative predictive value was 99.3%. The difference between JPEG images and bit-map images in the detection of vision-threatening referable disease amounted to a disagreement about the presence of one microaneurysm in one image, which did not require subsequent laser photocoagulation.

Using highest-quality compressed JPEG images (Paintshop Pro) does not appear to result in any loss of sensitivity when compared with uncompressed bit-map images for detecting potentially vi-

sion-threatening disease. This finding helps confirm earlier pilot studies (3,4). JPEG files compressed to highest-quality images result in file sizes that are 8% of the original bit-map image file size, which allows them to be more readily stored, more easily transferred across a web-interface, and transmitted at a faster rate.

GRAHAM P. LEESE, MD, FRCP^{1,2}
 ANGELA ELLINGFORD, BSC³
 ANDREW D. MORRIS, MD, FRCP^{1,2}
 JOHN D. ELLIS, MPH, FRCOPHTHAL³
 SCOTT CUNNINGHAM, BSC¹

From the ¹Department of Diabetes, Ninewells Hospital and Medical School, Dundee, U.K.; the ²Department of Medicine, Ninewells Hospital and Medical School, Dundee, U.K.; and the ³Department of Ophthalmology, Ninewells Hospital and Medical School, Dundee, U.K.

Address correspondence to Dr. Graham Leese, Ward 1 and 2 Ninewells Hospital, Dundee DD1 9SY, U.K. E-mail: graham.leese@tuht.scot.nhs.uk.



References

1. Jackson W: Improving diabetic retinopathy screening (Editorial). *Diabetes Care* 25:1477-1478, 2002
2. Newsom RS, Clover A, Costen MT, Sadler J, Newton J, Luff AJ, Canning CR: Effect of digital image compression on screening for diabetic retinopathy. *Br J Ophthalmol* 85:799-802, 2001
3. Eikelboom RH, Yogesan K, Barry CJ, Constable IJ, Tay-Kearney ML, Jitskaia L, House PH: Methods and limits of digital image compression of retinal images for telemedicine. *Invest Ophthalmol Vis Sci* 41:1916-1924, 2000
4. Zeimer R, Zou S, Meeder T, Quinn K, Vitale S: A fundus camera dedicated to screening of diabetic retinopathy in the primary-care physicians office. *Invest Ophthalmol Vis Sci* 43:1581-1587, 2002

Indications That Phototherapy Is a Risk Factor for Insulin-Dependent Diabetes

In a previous study (1), we found that the diagnosis of maternal-child blood group incompatibility appeared as a risk factor for type 1 diabetes, but we were not able to disentangle possible treatment effects from that of diagnosis. A European population-based multicenter study confirmed the association of type 1 diabetes

Downloaded from http://ada.silverchair.com/care/article-pdf/26/1/256/648225/256b.pdf by guest on 17 April 2024

High Prevalence of Insulin Resistance and Metabolic Syndrome in Overweight/Obese Preadolescent Hong Kong Chinese Children Aged 9–12 Years

During the past decade, the rising prevalence of childhood obesity has been accompanied by a rapid increase in young-onset type 2 diabetes (1). The associations among obesity, insulin resistance, hypertension, and dyslipidemia are not well defined in preadolescent children. Furthermore, the impact of family history of diabetes, low birth weight, and non-breast-feeding on the clustering of features of insulin resistance syndrome in children remained to be determined. In a cross-sectional study of 271 primary school children between 9 and 12 years of age, we compared the effects of family history of diabetes, breast-feeding, and extremes of birth weight on obesity, insulin resistance, and cardiovascular risk factors between an obese/overweight ($n = 129$) and a nonobese group ($n = 142$). Anthropometric indexes, blood pressure, fasting plasma lipids, glucose, and insulin were measured. Family history of diabetes, birth weight, and feeding mode in the first 3 months of life were obtained from parents.

Overweight/obese children were taller and had higher systolic blood pressure, fasting triglycerides, fasting serum insulin, and insulin resistance index (homeostasis model assessment) but lower HDL cholesterol level than nonobese children (Table 1). The odds ratios for a family history of diabetes and formula feeding in overweight/obese children were 4.37 (95% CI 2.25–8.52, $P < 0.001$) and 2.20-fold (1.29–3.76, $P = 0.004$). Overweight/obese children had increased risk of high blood pressure (3.21 [1.60–6.45], $P = 0.001$), dyslipidemia (2.72 [1.58–4.66], $P < 0.001$), and hyperinsulinemia (defined as insulin level above the age- and sex-specific 85th percentile; 14.1 [7.75–25.48], $P < 0.001$). Nearly 50% of overweight/obese children had at least two of the three cardiovascular risk factors of dyslipidemia, high blood pressure, and hyperinsulinemia, and 8% had all three risk factors. Seventy-seven percent of overweight/obese children had insulin resistance, which was best predicted by waist circumference ($\beta = 0.52$, $P < 0.001$) and HDL cholesterol level ($\beta = -0.19$, $P = 0.001$) on multivariate analysis.

Clustering of cardiovascular risk factors is common in overweight/obese preadolescent children in Hong Kong. Overweight/obese children are more likely to have a positive family history of diabetes and formula milk-feeding in infancy. Our findings support the notion that breast-feeding may be associated with a reduction in childhood obesity risk (2). In agreement with the recent report

by Sinha et al. (3), >77% of overweight/obese children in the present study had hyperinsulinemia. Given the predictive value of insulin resistance on future development of type 2 diabetes and coronary heart disease (4,5), the high prevalence of insulin resistance in these preadolescent children is an important public health issue.

Acknowledgments—This study was supported by funding from the Research Grants Council of the Hong Kong Special Administrative Region (project no. CUHK 4060/00M) and the Hong Kong Foundation for Research and Development in Diabetes.

RITA Y.T. SUNG, MD, FRCP¹
 PETER C.Y. TONG, PHD, MRCP²
 CHUNG-WAH YU, MB, BS, MPhil¹
 PATRICK W.C. LAU, PHD³
 GEOFFREY T.F. MOK, MB, BS, MRCP¹
 MAN-CHING YAM, MB, BS, MRCP¹
 PEGGO K.W. LAM, MPhil⁴
 JULIANA C.N. CHAN, MD, FRCP²

From the ¹Department of Pediatrics, the Chinese University of Hong Kong, the Prince of Wales Hospital, Shatin, Hong Kong; the ²Department of Medicine & Therapeutics, the Chinese University of Hong Kong, the Prince of Wales Hospital, Shatin, Hong Kong; the ³Department of Physical Education, Hong Kong Baptist University, Kowloon, Hong Kong; and the ⁴Centre for Clinical Trials and Epidemiological Research, the Chinese University of Hong Kong, the Prince of Wales Hospital, Shatin, Hong Kong.

Address correspondence to Dr. Peter Tong, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong. E-mail: ptong@cuhk.edu.hk.

Table 1—Clinical characteristics and cardiovascular risk profiles in overweight/obese and nonobese Chinese preadolescent children

	Boys			Girls		
	Nonobese	Obese	P	Nonobese	Obese	P
n	67	84		75	45	
Age (years)	10.5 ± 1.1	10.4 ± 0.9	NS	10.4 ± 1.0	10.5 ± 1.1	NS
BMI (kg/m ²)	16.7 ± 1.7	24.7 ± 3.1	<0.001	16.5 ± 1.7	23.4 ± 2.4	<0.001
Birth weight (kg)	3.26 ± 0.50	3.39 ± 0.52	NS	3.18 ± 0.46	3.26 ± 0.46	NS
Waist circumference (cm)	61.1 ± 5.6	80.6 ± 8.0	<0.001	60.5 ± 4.8	75.2 ± 7.9	<0.001
Systolic blood pressure (mmHg)	98 ± 10	107 ± 9	<0.001	99 ± 10	107 ± 11	<0.001
Diastolic blood pressure (mmHg)	63.5 ± 11	67 ± 13.0	NS	64 ± 11	67 ± 11	NS
Fasting triglycerides (mmol/l)*	0.72 ×/÷ 1.38	0.96 ×/÷ 1.51	<0.001	0.77 ×/÷ 1.46	0.99 ×/÷ 1.53	<0.01
Fasting HDL cholesterol (mmol/l)	1.80 ± 0.37	1.41 ± 0.37	<0.001	1.65 ± 0.42	1.40 ± 0.33	<0.01
Fasting plasma glucose (mmol/l)	4.8 ± 0.3	4.8 ± 0.4	NS	4.7 ± 0.3	4.7 ± 0.4	NS
Fasting serum insulin (pmol/l)*	41.7 ×/÷ 1.9	110 ×/÷ 2.1	<0.001	57 ×/÷ 2.1	102.1 ×/÷ 1.8	<0.001
Insulin resistance index (HOMA)*	1.22 ×/÷ 1.9	3.22 ×/÷ 2.2	<0.001	1.66 ×/÷ 2.2	2.94 ×/÷ 1.8	<0.001

Data are means ± SD or *geometric means ×/÷ antilog SD. HOMA, homeostasis model assessment; NS, not significant.

7.4 ± 1.3, and 7.2 ± 1.2%; normal values <6.1%), plasma cholesterol (5.3 ± 1.2, 5.3 ± 1.0, and 5.3 ± 1.0 mmol/l), plasma HDL cholesterol (1.2 ± 0.3, 1.1 ± 0.3, and 1.2 ± 0.3 mmol/l), and plasma triglycerides (1.8 ± 1.1, 1.9 ± 0.9, and 1.9 ± 0.1 mmol/l) showed no statistically significant differences (all $P > 0.26$). After exclusion of the insulin-treated subjects, the differences were also not statistically significant. We also found no significant differences for men or women separately.

We conclude that, at least in our cohort of subjects with type 2 diabetes, the Glu27Gln polymorphism of the β 2-adrenergic receptor has no important effect on BMI, age at diagnosis of diabetes, metabolic control, or plasma lipids.

Acknowledgments—This work was supported by the Dutch Diabetes Research Foundation (Amersfoort, the Netherlands, DFN grant 97.114 to C.W. and T.W.v.H.).

JONATHAN H. VAN TILBURG, PHD¹
 CISCA WIJMENGA, PHD¹
 HARM VAN BAKEL, MSC¹
 LEIDA ROZEMAN, MSC¹
 PETER L. PEARSON, PHD¹
 TIMON W. VAN HAEFTEN, MD²

From the ¹Department of Medical Genetics, University Medical Center, Utrecht, the Netherlands; and the ²Department of Internal Medicine, University Medical Center, Utrecht, the Netherlands.

Address correspondence to Timon W. van Haefen, MD, Department of Internal Medicine, G 02.228, P.O. Box 85500, NL 3508 GA Utrecht, The Netherlands. E-mail: t.w.vanhaefen@azu.nl

References

1. Large V, Hellstrom L, Reynisdottir S, Lonqvist F, Eriksson P, Lannfelt L, Arner P: Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. *J Clin Invest* 100:3005–3013, 1997
2. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P, Hamstra A: The Q/E27 polymorphism in the beta2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins. *J Intern Med* 247:651–656, 2000
3. Rosmond R, Ukkola O, Chagnon M, Boucharde C, Bjorntorp P: Polymorphisms of the beta2-adrenergic receptor gene (ADBR2) in relation to cardiovas-

cular risk factors in men. *J Intern Med* 248:239–244, 2000

Decreased Glucagon-Like Peptide 1 Fasting Levels in Type 2 Diabetes

The significance of over- or under-production of glucagon-like peptide 1 (GLP-1) (7–36) amide in diabetes remains controversial (1,2). Although it has been proposed that at least one factor contributing to the pathogenesis of type 2 diabetes is desensitization of the GLP-1 receptor on β -cells (2), exogenous administration of GLP-1 in patients with type 2 diabetes fully normalizes fasting hyperglycemia and reduces postprandial glycemic increments (3). Also, the GLP-1 response to oral glucose is not altered in postmenopausal women with impaired glucose tolerance (2). The purpose of the present study was to establish any difference in the fasting state concentration of GLP-1 in type 2 diabetes as compared with the normal state.

We examined 26 subjects (12 men and 14 women) with type 2 diabetes who were aged 67.6 ± 10.09 years (means ± SD) and had a BMI of 29.2 ± 3.5 kg/m² and a diabetes duration of 137.0 ± 23.7 months. As a control group, we included 15 normal subjects (9 women and 6 men) who were aged 65.8 ± 8.01 years and had a BMI of 28.1 ± 3.7 kg/m². Patients with type 2 diabetes were treated by diet and were on metformin and/or sulfonylurea therapy with HbA_{1c} 6.81 ± 1.37% and fasting glucose 87.30 ± 5.20 mg/dl. Written consent was obtained from all participants. Blood samples were obtained at rest between 8:00 and 9:00 A.M. after an overnight fast and 24 h alcohol abstinence. Insulin and GLP-1 were measured using an enzyme-linked immunosorbent assay (AxSYM; Abbott Lab, North Abbott, IL) and competitive radioimmunoassay (Peninsula Lab, Belmont, CA), respectively.

Interestingly, GLP-1, displaying a normal distribution, exhibited a statistically significant decrease ($P < 0.001$) in type 2 diabetic patients (23.8 ± 3.17 pg/ml) compared with control subjects (76.4 ± 4.47), whereas the plasma insulin concentration was higher in type 2 di-

abetic subjects (20.9 ± 13.4 IU/ml) than in control subjects (9.8 ± 1.3), with the difference being statistically significant ($P < 0.03$).

Using linear regression analysis, we found that GLP-1 was more negatively correlated with insulin in the type 2 diabetic patients than in the normal subjects ($r = -0.64$, $P < 0.001$ vs. $r = -0.43$, $P = 0.040$). In addition, GLP-1 was also negatively correlated with HbA_{1c} in type 2 diabetic subjects at a statistical level ($r = -0.43$, $P = 0.037$). Interestingly, the results were independent of diabetes duration.

The physiological importance of the decreased fasting level of GLP-1 in type 2 diabetic patients requires further clarification. If it is a reflection of increased sensitivity of β -cell responsiveness to secretagogues, then this study further confirms previous findings on the existence of a negative feedback loop between GLP-1 and insulin secretion and provides further evidence for the importance of the entero-insular axis in the regulation of insulin secretion. Moreover, the dissociation of GLP-1 levels with the duration of the disease suggests an early impairment of the entero-insular axis.

IOANNIS N. LEGAKIS, MD
 COSTAS TZIORAS, MD
 COSTAS PHENEKOS, MD

From the Endocrinology Unit, Red Cross Hospital, Athens, Greece.

Address correspondence to Dr. Ioannis N. Legakis, 27 Navarinou St., Cholongos 155 62 Athens, Greece. E-mail: legakis@ath.forthnet.gr.

References

1. Orskov C, Jeppesen J, Madsbad Holst JJ: Proglucagon products in plasma of non-insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. *J Clin Invest* 87:415–423, 1991
2. Kieffer TJ, Habener JF: The glucagon-like peptides. *Endocr Rev* 20:876–913, 1999
3. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. *Diabetes Care* 22:1137–1143, 1999

Docosahexaenoic Acid But Not Eicosapentaenoic Acid Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients

The dyslipidemia of type 2 diabetes includes the accumulation of small dense LDL particles in plasma that have an increased propensity to glycation and oxidation and may contribute to the endothelial dysfunction in type 2 diabetic patients. We recently reported that both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the two major dietary long-chain n-3 fatty acids, significantly reduced triglycerides and increased HDL₂ cholesterol without changing total, LDL, or HDL cholesterol in a group of type 2 diabetic subjects (1). We now report additional data on the differential effects of EPA and DHA on LDL particle size in the same subjects.

Nonsmoking treated hypertensive diabetic men and postmenopausal women, aged 40–75 years, were stratified by sex, age, and BMI and randomized to receive 4 g/day purified EPA, DHA, or olive oil (placebo) for 6 weeks in a double-blinded trial. LDL particle diameter was determined by gradient gel electrophoresis (2).

At baseline there were no significant differences among the olive oil, EPA, and DHA groups in plasma LDL cholesterol level and LDL particle size (25.69 ± 0.13 nm, 26.0 ± 0.16 nm, and 25.74 ± 0.16 nm, respectively). Relative to placebo, LDL particle size was decreased by 0.12 ± 0.10 nm ($P = 0.49$) with EPA and increased by 0.26 ± 0.10 nm ($P = 0.02$) with DHA after adjusting for multiple comparisons (Bonferroni).

These data support our previous study in overweight hypercholesterolemic subjects, in whom LDL particle size increased after supplementation with DHA but not EPA (2). While the increase in LDL particle size with DHA supplementation seen in our present study appears relatively small, a significant difference in size of 1.02 nm distinguished between middle-aged healthy men with no risk factors and men with the

metabolic syndrome (3). The differential effects on LDL particle size after EPA and DHA cannot be explained by the reduction in triglycerides alone, since both EPA and DHA significantly decreased serum triglycerides by a similar extent relative to placebo (19 and 15%, respectively) (1). Additionally, the association between the change in LDL size and triglycerides was only weak ($r = -0.30$, $P = 0.04$).

Supplementation with purified DHA increases LDL particle size, reduces serum triglycerides, and increases HDL₂ cholesterol (1), as well as improves vascular function (4) and blood pressure (5). Therefore, for subjects with type 2 diabetes, DHA may have more therapeutic value than EPA as a food additive, but longer-term prospective studies are needed to address this issue.

RICHARD J. WOODMAN, MMedSci¹
TREVOR A. MORI, PHD¹
VALERIE BURKE, MD¹
IAN B. PUDDEY, MD¹
GERALD F. WATTS, MD, PHD¹
JAMES D. BEST, MD²
LAWRENCE J. BEILIN, MD¹

From the ¹Department of Medicine, the University of Western Australia, the West Australian Institute for Medical Research and West Australian Heart Research Institute, Royal Perth Hospital, Perth, Western Australia; and the ²Department of Medicine, University of Melbourne and St. Vincents Hospital, Melbourne, Australia.

Address correspondence to Richard Woodman, Department of Medicine, University of Western Australia, P.O. Box x2213, Perth, WA, Australia 6847. E-mail: rwoodman@cyllene.uwa.edu.au.

References

1. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ: Effects of purified eicosapentaenoic acid and docosahexaenoic acid on glycemic control, blood pressure and serum lipids in treated-hypertensive type 2 diabetic patients. *Am J Clin Nutr* 76:1007-1015, 2002
2. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. *Am J Clin Nutr* 71:1085-1094, 2000
3. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. *Arterioscler Thromb Vasc Biol* 20: 2140-2147, 2000

4. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ: Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. *Circulation* 102:1264-1269, 2000
5. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ: Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. *Hypertension* 34:253-260, 1999

The Human Insulin Analogue Aspart Is Not the Almighty Solution for Insulin Allergy

Although human insulin is beneficial for most diabetic patients, some patients suffer from an allergy to exogenous insulin. Human insulin analogues, lispro or aspart, have been well tolerated in cases of insulin allergy. However, we report herein the first case of allergy to both lispro and aspart.

A 53-year-old woman with a history of type 2 diabetes for the past 3 years consulted our hospital for management of uncontrolled diabetes. Her postprandial blood glucose level was 12.9 mmol/l, and her HbA_{1c} level was 10.2%. She was initially treated with oral hypoglycemic agents (voglibose, glimepiride, metformin, and pioglitazone), which led to a decrease in her HbA_{1c} to 6.8%. However, her hyperglycemia became difficult to control over the next year (HbA_{1c} 7.6%), and treatment with intermediate-acting human insulin (Novolet N; Novo Nordisk, Bagsvaerd, Denmark) was begun. Two months after starting insulin injections, the patient noticed a skin rash and itching at the injection sites, so her insulin was changed to the analogues aspart and lispro, in succession. The local reactions continued, however, and the insulin analogue injections were suspended.

The patient had no previous history of any allergy. The percentage of eosinophils in her peripheral white blood cell count was 8.0%. She showed a high level of total IgE (748 IU/ml; normal, <400 IU/ml) and human insulin-specific IgE (19.80 IU/ml; normal, <0.34) measured by radioallergosorbent test. She had a positive test for anti-insulin antibodies (52%; normal, <7%). Prick tests were

From the ¹Department of Rural Health, University of Melbourne, Melbourne, Australia; the ²Tianjin Center for Disease Control and Prevention, Tianjin, China; the ³Tianjin Institute for Women's Health, Tianjin, China; and the ⁴Tianjin Public Health Bureau, Tianjin, China.

Address correspondence to Bridget Hsu-Hage, School of Rural Health, Faculty of Medicine, University of Melbourne, PO Box 6500, Shepparton, Victoria 3632, Australia. E-mail: bhage@unimelb.edu.au.

References

1. Yang X, Hsu-Hage B, Zhang H, Yu L, Dong L, Li J, Shao P, Zhang C: Gestational diabetes mellitus in women of single gravidity in Tianjin City, China. *Diabetes Care* 25:847-851, 2002
2. Yang X, Hsu-Hage B, Yu L, Simmons D: Selective screening for gestational diabetes in Chinese women (Letter). *Diabetes Care* 25:796, 2002
3. Yang X, Hsu-Hage B, Zhang H, Zhang C, Zhang Y, Zhang C: Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. *Diabetes Care* 25:1619-1624, 2002
4. Fagen C, King JD, Erick M: Nutrition management in women with gestational diabetes mellitus: a review by ADA's Diabetes Care and Education Dietetic Practice Group. *J Am Diet Assoc* 95:460-467, 1995
5. Pan X-R, Yang W-Y, Li G-W, Liu J: Prevalence of diabetes and its risk factors in China, 1994. *Diabetes Care* 20:1664-1669, 1997

COMMENTS AND RESPONSES

Thyroid Stimulating Hormone Screening Is More Sensitive for Detecting Thyroid Abnormalities in Children and Adolescents With Type 1 Diabetes

Kordonouri et al. (1) provide interesting information regarding the frequency of thyroid autoimmunity in pediatric-aged patients with type 1 diabetes. Their recommendations of "yearly examinations of thyroid antibodies" and

"in cases of thyroid antibody positivity, thyroid function tests and ultrasound assessment" "to minimize the risk of undiagnosed hypothyroidism in young patients with type 1 diabetes" are not supported by the data. If the goal is to detect subjects with hypothyroidism, then as shown in Table 1 of their study, 15.8% (241) of 1,530 patients who were thyroid antibody positive had an elevated thyroid stimulating hormone (TSH) and would be considered true positives; 7.8% (434) of 5,567 thyroid antibody-negative patients had an elevated TSH and would be considered false negatives. Thus, the sensitivity [true positives/(true positives + false negatives)] for thyroid antibody testing equals 35%. There were 5,133 antibody-negative patients with normal TSH values (true negatives) and 1,289 thyroid antibody-positive TSH-normal patients. Thus, the specificity [true negatives/(true negatives + false positives)] for thyroid antibody testing in their study was 80%. In regard to patients requiring thyroxine treatment, 10.6% (162) of the antibody-positive patients were true positives (antibody positive and thyroxine treated) and 0.6% (33) of the antibody-negative patients were false negatives (antibody negative and thyroxine treated). In addition, there were 5,534 true negatives (antibody negative, no treatment) and 1,388 false positives (antibody positive, no treatment). Thus, antibody testing was 83% sensitive and 80% specific.

Since there is no proven benefit in treating antibody-positive patients with normal TSH levels (2), and since screening tests should be highly sensitive, the data actually support yearly primary TSH screening with possible secondary antibody testing.

ROBERT P. HOFFMAN, MD

From The Ohio State University College of Medicine and Public Health, Department of Pediatrics, Columbus, Ohio.

Address correspondence to Robert P. Hoffman, MD, Children's Hospital ED541, 700 Children's Dr., Columbus, OH 43205. E-mail: hoffmanr@pediatrics.ohio-state.edu.

References

1. Kordonouri O, Klinghammer A, Lang EB, Grütters-Kieslich A, Grabert M, Holl RW: Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. *Diabetes Care* 25:1346-1350, 2002

2. Rother KI, Zimmerman D, Schwenk WF: Effect of thyroid hormone treatment on thyromegaly in children and adolescents with Hashimoto disease. *J Pediatr* 124:599-601, 1994

Thyroid Antibody Screening in Children and Adolescents With Type 1 Diabetes

Response to Hoffman

We thank Dr. Hoffman for his critical comments (1). According to his calculations, based on our cross-sectional study data, he found a specificity of 80% and only a low sensitivity of 35% for the thyroid antibody-screening test. Thus, he does not support our recommendation for yearly examinations of thyroid antibodies (2).

We agree with him that screening tests should be highly sensitive, but the data of our multicenter study do not allow a true estimation of the sensitivity, since patients have not been followed longitudinally and since we missed those patients who will develop hypothyroidism later on during their course of diabetes. Indeed, we examined patients with type 1 diabetes at the Pediatric Diabetes Outpatient Clinic of the Otto-Heubner-Center, Charité, Berlin, and found that 8 of 16 patients with positive antibodies developed thyroid stimulating hormone (TSH) elevation after an observation time of 2-6 years (median 3.5) (3). Therefore, patients with positive antibodies should be monitored for TSH elevation at yearly intervals.

In addition, the German Association of Pediatric and Adolescent Medicine recommends that patients with positive thyroid antibodies and concomitant thyroid gland enlargement with a typical hypoechogenic pattern in ultrasound studies should receive treatment with L-thyroxine.

For these reasons, we have been performing thyroid antibody-screening tests at our institution in all patients with diabetes since 1998.

OLGA KORDONOURI, MD¹
REINHARD HARTMANN, MD¹
REINHARD W. HOLL, MD²

Downloaded from http://ada.silverchair.com/care/article-pdf/26/1/256/648225/256b.pdf by guest on 17 April 2024

From the ¹Clinic for General Pediatrics, Otto-Heubner Centrum, Charité, Campus Virchow-Klinikum, Humboldt University, Berlin, Germany; and the ²Department of Biomedical Engineering, Ulm University, Ulm, Germany.

Address correspondence to Olga Kordonouri, MD, Klinik für Allgemeine Pädiatrie, Otto-Heubner-Centrum, Charité, CVK, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: olga.kordonouri@charite.de.

References

- Hoffman RP: Thyroid stimulating hormone screening is more sensitive for detecting thyroid abnormalities in children and adolescents with type 1 diabetes (Letter). *Diabetes Care* 26:255, 2003
- Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M, Holl RW, on behalf of the DPV-Initiative of the German Working Group for Pediatric Diabetology: Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. *Diabetes Care* 25: 1346–1350, 2002
- Kordonouri O, Deiss D, Danne T, Dorow A, Bassir C, Grüters-Kieslich A: Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with type 1 diabetes. *Diabet Med* 19:518–521, 2002

Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product

A recent article by Metzger et al. (1) questioned the reproducibility of the continuous glucose monitoring system (CGMS; Medtronic MiniMed). We were surprised by the authors' conclusions, as their results were consistent with previously published reports. We believe the authors' expectations for the CGMS did not coincide with its intended use. We were also puzzled by their use of a subjective assessment of clinical decision making when a validated tool, i.e., the Clarke error grid, is available (2). Finally, Metzger et al. dismissed the impact of an update to the CGMS software (Solutions 3.0) that does in fact improve the reproducibility evident in their data.

Although Metzger et al. reported re-

sults based on a limited number of subjects ($n = 11$), the results are quite similar to those reported in a large postmarketing study ($n = 235$) (3). Correlation was 0.93 mg/dl (vs. 0.91), and bias was 0.0 mg/dl (vs. -3.91). Metzger et al. also reported that 69% of sensor-sensor pairs had $>10\%$ difference, which compares closely with the previously reported median difference of 12.6% between sensor-meter pairs. Even the meters used to calibrate the CGMS provide only 56 to 69% of self-monitored blood glucose values within 10% of corresponding laboratory results (4).

As stated in the instructions for use, information provided by the CGMS "is intended to supplement, not replace, blood glucose information using standard home glucose monitoring devices" by providing glucose pattern and trend information for 24–72 h. Metzger et al. stated, "Clinical decisions should not be made on the sole basis of glucose sensor data" (1). When used with self-monitored blood glucose and HbA_{1c} values, clinical decisions based on CGMS profiles are designed to help the diabetes team optimize management.

Metzger et al. included several figures depicting discrepancies between sensor-sensor profiles, the most obvious being patient K. The authors failed to note that the sensor software labeled the depressed tracing as not meeting optimal accuracy criteria and that it therefore should have been further investigated by the clinician before use. The authors further report a 35% discrepancy in the clinical interpretation of sensor-sensor profiles. This method of assessment is subjective and has not been validated. Moreover, based on a Clarke error grid analysis, $>93\%$ of the CGMS readings are clinically accurate or acceptable.

Metzger et al. report technical problems in 18% of the profiles generated by Solutions 2.0 software. The upgraded Solutions 3.0 software resolves many of the technical reasons for which data were discarded in their analysis, corrects the abrupt shift in value at midnight, improves the accuracy and reproducibility of the data downloads, and improves the agreement between sensor and meter values as measured by mean absolute percent difference (18.4 vs. 16.1%) and correlation (0.91 vs. 0.92) (5).

An established body of literature, including a supplement to the journal *Di-*

abetes Technology & Therapeutics (6), supports the performance and utility of the CGMS to guide therapy adjustments based on glycemic excursions and to improve and predict HbA_{1c}. The results reported by Metzger et al. should be weighed against the encouraging results and conclusions of both evolving and previously reported research.

JOHN J. MASTROTOTARO, PHD
TODD M. GROSS, PHD

From Medtronic MiniMed, Northridge, CA.

Address correspondence to Dr. John J. Mastrototaro, Medtronic MiniMed, 18000 Devonshire St., Northridge, CA 91325-1219. E-mail: john.mastrototaro@minimed.com.

References

- Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I: Reproducibility of glucose measurements using the glucose sensor. *Diabetes Care* 25:1185–1191, 2002
- Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 8:307–310, 1986
- Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ: Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. *Diabetes Technol Ther* 2:49–56, 2000
- Poirier J-Y, Le Prieur N, Campion L, Guilhem I, Allannic H, Maugeudre D: Clinical and statistical evaluation of self-monitoring blood glucose meters. *Diabetes Care* 21:1919–1924, 1998
- Shin JJ, Dangui ND, Kanderian S Jr, Gross TM, Mastrototaro JJ: A new retrospective calibration algorithm (New-RA) for continuous glucose monitoring provides more complete and more accurate CGMS data (Abstract). *Diabetes* 51(Suppl. 2): A207, 2002
- Skyler JS, Klonoff DC, Grodsky GM (Eds.): Advances in continuous glucose monitoring in diabetes mellitus. *Diabetes Technol Ther* 2 (Suppl. 1):1–97, 2000

Response to Mastrototaro and Gross

We thank Mastrototaro et al. (1) for their comments. For more than 30 years, development of a reliable ambulatory continuous glucose monitor has appeared to be an insur-

mountable technological challenge. The Medtronic MiniMed continuous glucose monitoring system (CGMS), the first commercially available system, provides retrospective analysis of glucose levels, making confirmation of unexpected findings difficult. As stated by Mastrototaro et al., when our sensor data were evaluated using correlation tests, a high degree of correlation with capillary blood measurements was found, confirming several previous reports. However, simple correlation tests do not identify potentially important clinical discrepancies. The tools to evaluate the clinical efficacy of new monitoring systems are limited. We did not use the Clarke error grid because the boundaries used in the published version (2) are not consistent with the requirements of tight glycemic control. For example, reference/sensor glucose value pairs such as 200 vs. 90 or 80 vs. 160 would fall into the acceptable “B” zone, although today such differences are unacceptable. Indeed, in the data reported by Gross et al. (3), many points falling in the B zone may not be considered clinically acceptable today. Therefore, pending the publication of a validated modern version of the Clarke error grid or another validated tool, we used an admittedly more subjective tool, the clinical judgment of a diabetologist blinded to the subject’s identity.

Our profiles were generated using So-

lutions version 2 software, which was the version available at the time of the study and the one used in most previously published reports. Recalculation of our data with the newer software showed significant improvement, particularly in correcting the “midnight shift.” However, other discrepancies apparent in our study, and our ultimate conclusions, were unchanged.

Recently, McGowan et al. (4) used a different technique to validate CGMS readings in seven patients and found that in four, falsely low sensor readings “might have resulted in inappropriate reduction of overnight insulin dose,” a finding that supports our results. They conclude that many hypoglycemic episodes identified by the sensor may be spurious, thus questioning recent reports that showed an unexpectedly high incidence of asymptomatic nocturnal hypoglycemia.

We recognize the importance of this new technology and its inherent technical difficulties. We applaud Medtronic MiniMed for producing the first commercial system and for their continuing efforts to improve its reliability. The need for continued development is obvious, and clearly this technology will greatly improve our ability to treat diabetes. However, the current model has limitations that must be recognized, and new tools are needed to critically evaluate the clinical reliability of future devices.

MURIEL METZGER, MD¹
GIL LEIBOWITZ, MD¹
JULIO WAINSTEIN, MD²
BENJAMIN GLASER, MD¹
ITAMAR RAZ, MD¹

From the ¹Diabetes Center, Endocrinology and Metabolism Service, Hadassah University Hospital, Jerusalem, Israel, and the ²Diabetes Unit, Wolfson Hospital, Holon, Israel.

Address correspondence to Dr. Muriel Metzger, Diabetes Unit, Hadassah University Hospital, P.O. Box 12000, Jerusalem, Israel. E-mail: muriel@hadassah.org.il.

References

1. Mastrototaro JJ, Gross TM: Reproducibility of the continuous glucose monitoring system matches previous reports and the intended use of the product (Letter). *Diabetes Care* 26:256, 2002
2. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL: Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes Care* 10:622–628, 1987
3. Gross TM, Bode BW, Einhorn D, Kaye DM, Reed JH, White NH, Mastrototaro JJ: Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. *Diabetes Technology & Therapeutics* 2:49–56, 2000
4. McGowan K, Thomas W, Moran A: Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 2 diabetes. *Diabetes Care* 25:1499–1503, 2002